Open AccessLow Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study
Author(s) -
Victoria D. Ojeda,
K Rivet Amico,
James P. Hughes,
Ethan Wilson,
Maoji Li,
Timothy H. Holtz,
Anupong Chitwarakorn,
Robert M. Grant,
Bonnie J. Dye,
LindaGail Bekker,
Sharon Mannheimer,
Mark A. Marzinke,
Craig W. Hendrix
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002103
Subject(s) - pre exposure prophylaxis , emtricitabine , medicine , dosing , gee , men who have sex with men , regimen , generalized estimating equation , family medicine , human immunodeficiency virus (hiv) , demography , clinical psychology , viral load , antiretroviral therapy , statistics , mathematics , syphilis , sociology
We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg.